Showing 3681-3690 of 6808 results for "".
- Endo Removes Qwo from Market Due to Concerns About Injection Site Bruising, Skin Discolorationhttps://practicaldermatology.com/news/endo-removes-qwo-from-market-due-to-concerns-about-injection-site-bruising-skin-discoloration/2461467/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- UCB's Bimekizumab Performs Well in Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-hidradenitis-suppurativa/2461464/UCB’s bimekizumab may be a promising treatment approach in adults with moderate to severe hidradenitis suppurativa, according to topline results from two Phase 3 studies, BE HEARD I and BE HEARD II. The positive results from these two studies will form the basis of global reg
- Hydrafacial, DOCTOR BABOR Collab for New Collagen HA Boosterhttps://practicaldermatology.com/news/hydrafacial-doctor-babor-collab-for-new-collagen-ha-booster/2461461/The Beauty Health Company’s Hydrafacial launched a new booster co-created with BABOR Skincare. The new DOCTOR BABOR Collagen HA booster is inspired by DOCTOR BABOR’s formulations and developed with the BABOR Laboratories in Germany. “Hydrafacial has cre
- UCB’s Bimekizumab Performs Well in PsA Studieshttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-psa-studies/2461460/Two new studies highlight the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and/or tumor necrosis factor inhibitor inadequate responders (TNFi-IR). The 24-week results from the Phase 3 BE OPTIMAL study and 16-w
- Galderma Sponsors 21st Annual SCOPE Miami Beach 2022 Art Showhttps://practicaldermatology.com/news/galderma-sponsors-21st-annual-scope-miami-beach-2022-art-show/2461447/Galderma is the exclusive aesthetic injectables sponsor of the 21st annual SCOPE Miami Beach 2022 art show. Galderma will be highlighting its aesthetics portfolio – Restylane, Dysport (abobotulinumtoxinA) and Sculptra – and hosting a variety of
- Wireless Smart Bandage May Speed Wound Healinghttps://practicaldermatology.com/news/wireless-smart-bandage-may-speed-wound-healing/2461444/A new wireless smart bandage may speed up tissue repair by monitoring the wound healing process and treating the wound simultaneously, according to research in Nature Biotechnology. The device promotes faster closure of wounds, increases new blood flow to injured tissue, and enhanc
- AD News: Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapyhttps://practicaldermatology.com/news/ad-news-alphyn-biologics-completes-first-cohort-of-phase2a-clinical-trial-of-topical-therapy-1/2461432/Alphyn Biologics completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mil
- Reistone Biopharma's Oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for ADhttps://practicaldermatology.com/news/reistone-biopharmas-oral-ivarmacitinib-meets-primary-endpoint-in-phase-iii-study-for-ad/2461431/Reistone Biopharma’s once daily Ivarmacitinib as monotherapy relieves in improving skin inflammation and itchiness n adults and adolescents with moderate-to-severe, according to a results from thePhase III QUARTZ3 study. The study evaluated the efficacy and safety of once dai
- Beekman 1802 Gives Back: Brand Celebrates World Kindness Dayhttps://practicaldermatology.com/news/beekman-1802-gives-back-brand-celebrates-world-kindness-day/2461426/Beekman 1802 will celebrate World Kindness Day, an international holiday to promote kindness throughout the world. Root
- Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in PsA, Non-Radiographic Axial Spondyloarthritis, and AShttps://practicaldermatology.com/news/bimekizumab-demonstrated-sustained-clinical-responses-to-week-52-in-phase-3-studies-in-psa-non-radiographic-axial-spondyloarthritis-and-as/2461422/Bimekizumab demonstrated sustained clinical responses to Week 52 in Phase 3 studies in psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.. The findings were presented at the ACR Convergence 2022 in Philadelphia, November 10–14, 2022. <